Timing and sequence of vaccination against COVID-19 and Influenza
Phase 4
Completed
- Conditions
- CoronaCOVID-191004743810024970
- Registration Number
- NL-OMON51262
- Lead Sponsor
- Radboud Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 160
Inclusion Criteria
Age equal to or above 60 years
Received a COVID-19 vaccine 4-12 months prior to enrollment
Exclusion Criteria
History of COVID-19 infection (confirmed by a microbiological test)
Vaccination against influenza <6months
Immunocompromised (either by co-morbidities or induced by medication)
Known allergy or history of anaphylaxis or other serious adverse reactions to
vaccines
Acute illness < 2 weeks
Participation in another drug trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method